(AXSM) Axsome Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AXSM) Axsome Therapeutics, Inc. Complete Analysis Pack
See the Bigger Picture
This Axsome Therapeutics, Inc. BCG Matrix is a company-specific strategic tool used to assess how its products or business units fit across Stars, Cash Cows, Question Marks, and Dogs. The content on this page is a real preview of the actual analysis, so you can see the format and depth before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Auvelity for MDD
Auvelity, approved in 2022, is Axsome Therapeutics, Inc.'s lead commercial brand for major depressive disorder and sits in the Stars quadrant. In 2024, Axsome reported Auvelity net product revenue of $139.5 million, up 85% year over year, showing fast uptake in the large U.S. antidepressant market. With tens of millions of U.S. adults affected by depression, the brand has clear room to scale.
AXS-05 oral first-in-class profile
AXS-05, branded as Auvelity, is a first-in-class oral treatment for major depressive disorder, approved by the U.S. FDA in 2022. Its dextromethorphan-bupropion combo is different from standard antidepressants, and that supports premium pricing and repeat use. In Axsome Therapeutics, Inc. BCG terms, Auvelity fits a Star if uptake stays strong and prescriber adoption keeps scaling.
U.S. commercial rollout
Axsome Therapeutics, Inc. is still scaling its U.S. specialty CNS sales force, and that keeps the commercial rollout in Star territory. New prescriber adoption is the main growth lever, while promotion spend stays heavy to drive trial and repeat use. The setup fits a Star because high selling costs support fast share gains in a growing CNS market.
Large MDD market
MDD is one of the largest CNS markets in the U.S., with about 21 million adults affected each year, so the addressable pool is broad. That scale keeps demand deep for new options and supports long revenue runway for Axsome Therapeutics, Inc. if adoption stays strong.
In a large market, even modest share gains can matter. The size of MDD helps Axsome Therapeutics, Inc. expand sales while it builds awareness and access.
- ~21 million U.S. adults affected yearly
- Broad, recurring treatment pool
- Large market supports share gains
2025 growth engine
Auvelity is Axsome Therapeutics, Inc.’s clearest Star in 2025, because it is the company’s most visible growth engine and the main swing factor in near-term valuation. The market is still pricing Axsome around this brand’s uptake, so every sales update matters. This is the asset that can keep growth fast enough to defend the multiple.
- Auvelity drives 2025 growth.
- Valuation tracks its sales trend.
- Best Star asset in the portfolio.
Auvelity Powers Axsome’s Growth as 2024 Sales Jump 85%
Auvelity is Axsome Therapeutics, Inc.'s Star asset: 2024 net product revenue reached $139.5 million, up 85% year over year. Its first-in-class MDD profile and Axsome Therapeutics, Inc.'s expanding CNS sales force support fast share gains in a large U.S. depression market. If adoption keeps rising, this brand can keep driving valuation.
| Star metric | Value |
|---|---|
| Auvelity 2024 revenue | $139.5M |
| YoY growth | 85% |
| Role | Lead Star |
What is included in the product
Detailed Word Document
Axsome’s BCG Matrix maps its FDA-led growth drugs as Stars, pipeline bets as Question Marks, and minimal Cash Cows/Dogs.
Editable Excel File
Clean, one-page Axsome Therapeutics BCG Matrix to quickly spot pain points and portfolio priorities for decision-making
Reference Sources
Shows the Axsome Therapeutics, Inc. reference sources behind key claims, boosting credibility and speeding confident decision-making.
Cash Cows
Sunosi for EDS
Sunosi is Axsome Therapeutics, Inc.'s mature wake-promoting drug, with 2 approved uses: excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. Its chronic, repeat-use demand makes sales steadier than Axsome Therapeutics, Inc.'s growth drugs, so it fits the Cash Cow box in BCG terms.
Approved 2019
Sunosi, approved in 2019, is Axsome Therapeutics, Inc.’s older launch, so by FY2025 it has about 6 years of commercialization behind it. That age usually means lower incremental launch spend, since the brand is past the heavy awareness-build phase. In BCG terms, it fits a Cash Cow profile better than Axsome Therapeutics, Inc.’s newer assets because it is closer to a mature franchise than a growth-stage launch.
Established narcolepsy use
Narcolepsy is a recurring treatment market, and Sunosi already has an established base of patients and prescribers, which supports repeat revenue with less launch volatility. Axsome Therapeutics, Inc. benefits because refills and long-term use tend to be steadier than first-time adoption, making this a classic cash cow profile.
OSA-related EDS
OSA-related EDS is a larger, steadier market: obstructive sleep apnea affects about 1 billion adults worldwide, and Sunosi serves the already defined residual EDS niche. That low-growth but durable demand profile fits a Cash Cow, with recurring use in a stable category.
- Large, slow-moving OSA EDS pool
- Sunosi sits in a defined niche
- Stable demand supports cash flow
Axsome’s stable revenue base
Axsome Therapeutics, Inc.'s Sunosi is the closest thing to a cash cow: it still sells in sleep-wake disorders and gives Axsome a recurring revenue stream while Auvelity and the pipeline grow. In 2025, that steady product base helped fund R&D and commercial launches, which is the classic Cash Cow job.
Sunosi is not Axsome Therapeutics, Inc.'s biggest growth engine, but it is the most stable one. That matters because cash from an established product can support higher-spend launches without leaning as hard on outside capital.
- Sunosi supplies recurring sales
- Supports R&D and launch spend
- Acts like a classic Cash Cow
Sunosi: Axsome’s Reliable Cash Cow Funding Growth
Sunosi is Axsome Therapeutics, Inc.'s clearest Cash Cow: a 2019 launch with steady repeat use in narcolepsy and OSA-related EDS, so it brings recurring revenue with less launch spend. In FY2025, it helped fund R&D and newer launches while Axsome Therapeutics, Inc. pushed growth assets.
| Asset | FY2025 role | Why Cash Cow |
|---|---|---|
| Sunosi | Steady sales | Mature, repeat-use market |
Preview the Actual Deliverable
Axsome Therapeutics, Inc. Reference Sources
You're previewing the exact Axsome Therapeutics, Inc. BCG Matrix document you'll receive after purchase. The file is fully formatted and ready to use—no demo content or hidden placeholders. What you see here is the same professional report that will be delivered instantly after checkout.
Dogs
No major dog brand disclosed
In 2025, Axsome Therapeutics, Inc. stayed focused on approved and late-stage CNS assets, so no major legacy brand stood out as a low-share drag. The dog quadrant is effectively empty. That points to a portfolio built for growth, not brand cleanup.
No terminal commercial decline
Axsome Therapeutics, Inc. does not show a broad base of mature, declining drugs. Its main marketed products are still early in their life cycles: Sunosi was approved in 2019 and Auvelity in 2022, so they are still building uptake rather than entering terminal decline. That makes a true Dog unlikely in the current BCG view.
No divestiture candidate flagged
Axsome Therapeutics, Inc. had no clear divestiture candidate in 2025: its commercial mix was still centered on 2 marketed products, AUVELITY and SUNOSI, so there was no obvious deadweight brand to sell. That means no divestiture-driven cash trap was visible.
No commoditized franchise
Axsome Therapeutics is not a commoditized, generic-heavy story; it sells differentiated CNS drugs, led by AUVELITY and SUNOSI. In 2024, revenue reached about $495.5 million, showing a growth profile that does not fit a low-share, low-growth "Dog".
- Differentiated CNS focus
- Not generic-franchise driven
- 2024 revenue: $495.5 million
- Growth profile is not low-share/low-growth
Dog risk stays limited
As of end-2025, Axsome Therapeutics, Inc. had not disclosed a meaningful low-growth, low-share commercial loser, so Dog risk stayed limited. The main commercial base remained Auvelity and Sunosi, while pipeline misses could still create a future Dog if development fails. So far, the BCG Dog quadrant is largely empty.
- End-2025: no clear Dog disclosed
- Commercial focus stayed on Auvelity, Sunosi
- Pipeline failure could create future Dog
Axsome Has No Dog: Growth Assets Still Lead
Axsome Therapeutics, Inc. had no clear Dog in 2025: Auvelity and Sunosi were still growth assets, and 2024 revenue reached $495.5 million. That leaves the Dog quadrant effectively empty, with no disclosed low-share, low-growth legacy brand to divest.
| Metric | Data |
|---|---|
| 2024 revenue | $495.5 million |
| Marketed products | Auvelity, Sunosi |
| Dog status | No clear Dog disclosed |
Question Marks
AXS-07 2025 migraine launch
AXS-07, branded Symbravo, launched in 2025 for acute migraine in a U.S. market with about 39 million migraine sufferers and roughly 4.3 million monthly preventive users. As a fresh launch, Axsome Therapeutics, Inc. has early share and low penetration, so it fits the Question Mark box. If uptake scales, it could move toward a Star; if not, it stays a cash drain.
AXS-05 in Alzheimer’s disease agitation
AXS-05 in Alzheimer’s disease agitation is Axsome Therapeutics, Inc.'s late-stage expansion bet, but it has zero commercial share today, so it fits the Question Mark bucket. Alzheimer’s agitation remains a high-unmet-need CNS market, with no FDA-approved treatment in the U.S., so a win could open a large new revenue pool. Until approval and launch data arrive, it is still a pipeline asset, not a cash driver.
AXS-12 for narcolepsy
AXS-12 is a Question Mark because it is still in Phase III for narcolepsy and has no commercial sales yet. The narcolepsy market is real and growing, with treatment demand tied to a chronic disorder that affects about 1 in 2,000 people. If Phase III data show strong efficacy and tolerability, AXS-12 could move toward Star status; if not, its value stays uncertain.
AXS-14 for fibromyalgia
AXS-14 is still a Question Mark in Axsome Therapeutics, Inc.’s BCG mix: it is in Phase III for fibromyalgia, but it has no approved sales yet. Fibromyalgia remains a large chronic pain market, affecting about 4 million U.S. adults and often leading to years of drug use, so the upside is real if the trial data and filing land well.
That said, the asset still has zero market share and no revenue, so it is only a growth option today. In BCG terms, the bet is on converting a huge unmet-need market into sales; until approval and uptake are proven, AXS-14 stays a Question Mark.
- Phase III asset, no approved sales.
- Fibromyalgia affects about 4 million U.S. adults.
- High unmet need supports future growth.
- Zero market share keeps it a Question Mark.
AXS-05 smoking cessation
AXS-05 smoking cessation is a Question Mark in Axsome Therapeutics, Inc.’s BCG mix: it has upside, but no market share yet. Axsome has tested it in smoking cessation, including a Duke collaboration, but the data set is far smaller than the MDD franchise. The asset still needs stronger proof before it can compete for meaningful value.
- Upside exists, but no share yet.
- Duke work adds early clinical support.
- Evidence base is smaller than MDD.
Axsome’s High-Upside Question Marks: Big Potential, No Proven Engine Yet
Axsome Therapeutics, Inc.'s Question Marks are its high-upside, low-share bets: AXS-07 launched in 2025, while AXS-05, AXS-12, and AXS-14 still have no approved sales. Each targets a large CNS market, but all remain cash uses until approval and uptake prove demand. In BCG terms, they are growth options, not current engines.
| Asset | Status | BCG |
|---|---|---|
| AXS-07 | 2025 launch | Question Mark |
| AXS-05 | Pipeline | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.